Relationship Between Plasma 8-OH-Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial

Merlin C Thomas, Mark Woodward, Qiang Li, Raelene Pickering, Christos Tikellis, Neil Poulter, Mark E Cooper, Michel Marre, Sophia Zoungas, John Chalmers, ADVANCE Collaborative Group, Merlin C Thomas, Mark Woodward, Qiang Li, Raelene Pickering, Christos Tikellis, Neil Poulter, Mark E Cooper, Michel Marre, Sophia Zoungas, John Chalmers, ADVANCE Collaborative Group

Abstract

Background: 8-Oxo-2'-deoxyguanosine (8-oxo-2'-dG) is a biomarker of oxidative DNA damage that is associated with cardiovascular disease and premature mortality in the general population. Although oxidative stress has a proven role in cardiovascular complications in diabetes mellitus, evidence for a relationship between plasma 8-oxo-2'-dG and major cardiovascular outcomes in diabetes mellitus is weak.

Methods and results: A case-cohort study was performed in 3766 participants with prevalent diabetes mellitus in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial (ClinicalTrials.gov number NCT00145925). The hazard ratios for mortality and major acute cardiovascular events were derived using Cox regression models. During a median of 5 years of follow-up, 695 (18.4%) participants in this enriched cohort died (including 354 deaths from cardiovascular disease). Individuals with higher levels of 8-oxo-2'-dG were more likely to die. After adjusting for cardiovascular disease risk factors, the hazard ratio for a 1-SD increase in plasma 8-oxo-2'-dG was 1.10 (95% confidence interval, 1.01-1.20; P=0.03). This was driven by an independent association between plasma 8-oxo-2'-dG and cardiovascular death (hazard ratio, 1.23; 95% confidence interval, 1.10-1.37 [P<0.001]). By contrast, no association was seen between 8-oxo-2'-dG and noncardiovascular disease death (of which cancer was the major single cause). 8-Oxo-2'-dG was also not significantly associated with either nonfatal myocardial infarction or nonfatal stroke.

Conclusions: In adults with type 2 diabetes mellitus, increased levels of 8-oxo-2'-dG are independently associated with all-cause mortality and cardiovascular mortality in adults with longstanding type 2 diabetes mellitus who participated in the ADVANCE trial, consistent with the role of oxidative damage in the development and progression of cardiovascular decompensation in diabetes mellitus.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00145925.

Keywords: cardiovascular outcomes; mortality; oxidative stress; survival analysis; type 2 diabetes mellitus.

© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

Figures

Figure 1
Figure 1
Cumulative survival curves for all primary outcomes by quarter of 8‐oxo‐2′‐deoxyguanosine (8‐oxo‐2′‐dG), adjusted as in model 3 in Table 1. Blue, red, and green lines correspond, in this order, to increasing tertiles of 8‐ox‐dG. CVD indicates cardiovascular disease.
Figure 2
Figure 2
Hazard ratios (with 95% confidence intervals [CIs]) for all‐cause and cardiovascular death by predefined subgroups, adjusted as in model 3 in Table 1. eGFR indicates estimated glomerular filtration rate; HbA1c, glycated hemoglobin.

References

    1. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93:137–188.
    1. Ames BN. Endogenous oxidative DNA damage, aging, and cancer. Free Radic Res Commun. 1989;7:121–128.
    1. Valavanidis A, Vlachogianni T, Fiotakis C. 8‐hydroxy‐2′‐deoxyguanosine (8‐OHdG): a critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009;27:120–139.
    1. Kroese LJ, Scheffer PG. 8‐hydroxy‐2′‐deoxyguanosine and cardiovascular disease: a systematic review. Curr Atheroscler Rep. 2014;16:452.
    1. Di Minno A, Turnu L, Porro B, Squellerio I, Cavalca V, Tremoli E, Di Minno MN. 8‐hydroxy‐2‐deoxyguanosine levels and cardiovascular disease: a systematic review and meta‐analysis of the literature. Antioxid Redox Signal. 2016;24:548–555.
    1. Di Minno A, Turnu L, Porro B, Squellerio I, Cavalca V, Tremoli E, Di Minno MN. 8‐hydroxy‐2‐deoxyguanosine levels and heart failure: a systematic review and meta‐analysis of the literature. Nutr Metab Cardiovasc Dis. 2017;27:201–208.
    1. Machowska A, Sun J, Qureshi AR, Isoyama N, Leurs P, Anderstam B, Heimburger O, Barany P, Stenvinkel P, Lindholm B. Plasma pentosidine and its association with mortality in patients with chronic kidney disease. PLoS One. 2016;11:e0163826.
    1. Suzuki S, Shishido T, Ishino M, Katoh S, Sasaki T, Nishiyama S, Miyashita T, Miyamoto T, Nitobe J, Watanabe T, Takeishi Y, Kubota I. 8‐hydroxy‐2′‐deoxyguanosine is a prognostic mediator for cardiac event. Eur J Clin Invest. 2011;41:759–766.
    1. Susa T, Kobayashi S, Tanaka T, Murakami W, Akashi S, Kunitsugu I, Okuda S, Doi M, Wada Y, Nao T, Yamada J, Ueyama T, Okamura T, Yano M, Matsuzaki M. Urinary 8‐hydroxy‐2′‐deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure. Circ J. 2012;76:117–126.
    1. Broedbaek K, Siersma V, Henriksen T, Weimann A, Petersen M, Andersen JT, Jimenez‐Solem E, Stovgaard ES, Hansen LJ, Henriksen JE, Bonnema SJ, Olivarius Nde F, Poulsen HE. Urinary markers of nucleic acid oxidation and long‐term mortality of newly diagnosed type 2 diabetic patients. Diabetes Care. 2011;34:2594–2596.
    1. Broedbaek K, Siersma V, Henriksen T, Weimann A, Petersen M, Andersen JT, Jimenez‐Solem E, Hansen LJ, Henriksen JE, Bonnema SJ, de Fine Olivarius N, Friis S, Poulsen HE. Urinary markers of nucleic acid oxidation and cancer in type 2 diabetes. Redox Biol. 2015;4:34–39.
    1. Group AC , Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
    1. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–840.
    1. Study rationale and design of ADVANCE: action in diabetes and vascular disease—preterax and diamicron MR controlled evaluation. Diabetologia. 2001;44:1118–1120.
    1. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
    1. Hillis GS, Welsh P, Chalmers J, Perkovic V, Chow CK, Li Q, Jun M, Neal B, Zoungas S, Poulter N, Mancia G, Williams B, Sattar N, Woodward M. The relative and combined ability of high‐sensitivity cardiac troponin T and N‐terminal pro‐B‐type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care. 2014;37:295–303.
    1. Welsh P, Woodward M, Hillis GS, Li Q, Marre M, Williams B, Poulter N, Ryan L, Harrap S, Patel A, Chalmers J, Sattar N. Do cardiac biomarkers NT‐proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trial. Diabetes Care. 2014;37:2202–2210.
    1. Lowe G, Woodward M, Hillis G, Rumley A, Li Q, Harrap S, Marre M, Hamet P, Patel A, Poulter N, Chalmers J. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014;63:1115–1123.
    1. Schottker B, Brenner H, Jansen EH, Gardiner J, Peasey A, Kubinova R, Pajak A, Topor‐Madry R, Tamosiunas A, Saum KU, Holleczek B, Pikhart H, Bobak M. Evidence for the free radical/oxidative stress theory of ageing from the CHANCES consortium: a meta‐analysis of individual participant data. BMC Med. 2015;13:300.
    1. Mohammedi K, Bellili‐Munoz N, Marklund SL, Driss F, Le Nagard H, Patente TA, Fumeron F, Roussel R, Hadjadj S, Marre M, Velho G. Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all‐cause mortality in people with type 1 and type 2 diabetes. Cardiovasc Diabetol. 2015;14:845.
    1. Poulsen HE, Nadal LL, Broedbaek K, Nielsen PE, Weimann A. Detection and interpretation of 8‐oxodG and 8‐oxoGua in urine, plasma and cerebrospinal fluid. Biochem Biophys Acta. 2014;1840:801–808.
    1. Il'yasova D, Scarbrough P, Spasojevic I. Urinary biomarkers of oxidative status. Clin Chim Acta. 2012;413:1446–1453.
    1. Masugata H, Senda S, Inukai M, Himoto T, Imachi H, Murao K, Hosomi N, Okada H, Goda F. Association between oxidative stress assessed by urinary 8‐hydroxydeoxyguanosine and the cardiac function in hypertensive patients without overt heart disease. Clin Exp Hypertens. 2013;35:308–312.
    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA‐REG OUTCOME Investigators . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
    1. Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol. 2008;92:548–551.
    1. Pan HZ, Chang D, Feng LG, Xu FJ, Kuang HY, Lu MJ. Oxidative damage to DNA and its relationship with diabetic complications. Biomed Environ Sci. 2007;20:160–163.
    1. Ma D, Zhu W, Hu S, Yu X, Yang Y. Association between oxidative stress and telomere length in Type 1 and Type 2 diabetic patients. J Endocrinol Invest. 2013;36:1032–1037.
    1. Matzi V, Greilberger JF, Lindenmann J, Neuboeck N, Nuhsbaumer S, Zelzer S, Tafeit E, Maier A, Smolle‐Juettner MF. Application of hyperbaric oxygen reduce oxidative damage of plasmatic carbonyl proteins and 8‐OHdG by activating glutathion peroxidase. Clin Lab. 2015;61:587–593.
    1. Xu H, Watanabe M, Qureshi AR, Heimburger O, Barany P, Anderstam B, Eriksson M, Stenvinkel P, Lindholm B. Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. Perit Dial Int. 2015;35:206–215.
    1. Yeniova AO, Uzman M, Kefeli A, Basyigit S, Ata N, Dal K, Guresci S, Nazligul Y. Serum 8 hydroxydeoxyguanosine and cytotoxin associated gene a as markers for Helicobacter pylori infection. Asian Pac J Cancer Prev. 2015;16:5199–5203.
    1. Loffredo L, Marcoccia A, Pignatelli P, Andreozzi P, Borgia MC, Cangemi R, Chiarotti F, Violi F. Oxidative‐stress‐mediated arterial dysfunction in patients with peripheral arterial disease. Eur Heart J. 2007;28:608–612.
    1. Xiang F, Shuanglun X, Jingfeng W, Ruqiong N, Yuan Z, Yongqing L, Jun Z. Association of serum 8‐hydroxy‐2′‐deoxyguanosine levels with the presence and severity of coronary artery disease. Coron Artery Dis. 2011;22:223–227.
    1. Hu CW, Huang YJ, Li YJ, Chao MR. Correlation between concentrations of 8‐oxo‐7,8‐dihydro‐2′‐deoxyguanosine in urine, plasma and saliva measured by on‐line solid‐phase extraction LC‐MS/MS. Clin Chim Acta. 2010;411:1218–1222.
    1. Di Marco E, Jha JC, Sharma A, Wilkinson‐Berka JL, Jandeleit‐Dahm KA, de Haan JB. Are reactive oxygen species still the basis for diabetic complications? Clin Sci. 2015;129:199–216.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다